anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A parallel-group randomized controlled trial will be implemented with pregnant women at the antenatal clinics of the Aga Khan University Hospital (AKUH) Karachi. Pregnant women in their first trimester, registered or planning to register at AKUH with access to personal smartphones with internet connection will be considered eligible for the study. For pregnant women in the intervention arm, mobile health application will be provided on their smartphones that will screen their socio-demographic characteristics, diet and supplement use and physical activity habits. Based on the information provided by women, personalized recommendations and a dietary risk score will be generated upon completion of the questionnaire. A similar process will be repeated on 4 follow-ups, each 6 weeks apart after enrollment in the study. Also, push notifications consisting of tips and recommendations will be sent to women a maximum of 3 times a week on dietary, supplement use and physical activity. The women in the non-intervention arm will be provided with standard face-face counselling at similar time points as of intervention group, using the bilingual educational leaflet of the Aga Khan University Hospital "Diet during Pregnancy" and the American College of Obstetricians and Gynaecologists guidelines for physical activity during pregnancy. The primary outcome of the study is improvement in the dietary and supplement use that will be assessed through Dietary Risk Score. A selective subset of participants from both the group will undergo free of cost biochemical assessment micronutrients (serum calcium, vitamin D, iron and folate). The secondary outcomes include assessing the compliance and usability of m-Health application among the pregnant women enrolled in the intervention arm. Other secondary outcomes include evaluating the effect of m-Health coaching on maternal, newborn and infant outcomes among pregnant women in the intervention arm compared to the pregnant women in the non-intervention arm
Vitamin D possesses immunomodulatory functions and vitamin D deficiency has been associated with the rise in chronic inflammatory diseases, including asthma (Litonjua and Weiss, 2007). Vitamin D supplementation studies do not provide insight into the molecular genetic mechanisms of vitamin D-mediated immunoregulation. Here, we provide evidence for vitamin D regulation of two human chromosomal loci, Chr17q12-21.1 and Chr17q21.2, reliably associated with autoimmune and chronic inflammatory diseases. We demonstrate increased vitamin D receptor (Vdr) expression in mouse lung CD4+ Th2 cells, differential expression of Chr17q12-21.1 and Chr17q21.2 genes in Th2 cells based on vitamin D status and identify the IL-2/Stat5 pathway as a target of vitamin D signaling. Vitamin D deficiency caused severe lung inflammation after allergen challenge in mice that was prevented by long-term prenatal vitamin D supplementation. Mechanistically, vitamin D induced the expression of the Ikzf3-encoded protein Aiolos to suppress IL-2 signaling and ameliorate cytokine production in Th2 cells. These translational findings demonstrate mechanisms for the immune protective effect of vitamin D in allergic lung inflammation with a strong molecular genetic link to the regulation of both Chr17q12-21.1 and Chr17q21.2 genes and suggest further functional studies and interventional strategies for long-term prevention of asthma and other autoimmune disorders.
Myopia has been an increasing problem among school children, especially in Asian countries. High myopia is not only a refractive problem, but also a disease that can result in a number of sight-threatening complications such as macular degeneration, retinal detachment, glaucoma, and cataract. Atropine is a long-acting non-selective muscarinic antagonist that blocks accommodation by paralyzing ciliary muscles; it may affect remodeling of the sclera and suppress the elongation of axial length. Acupuncture and acupressure have been widely used in traditional Chinese medicine for thousands of years. Auricular acupoint stimulation by acupuncture or acupressure has been reported to improve visual acuity in myopic patients. Therefore, we want to compare the effect of myopia control between patients treated with low-concentration atropine eye drops combined with auricular acupoint stimulation and those who treated with atropine alone.
We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
BACKGROUND: With the increasing incidence of obesity and the childbearing-age delay among women, a debate over obesity's impacts on pregnancy and neonatal outcomes becomes hot. The potential negative effects of obesity and aging on fertility lead to an idea, whether an obese female pursuing IVF treatment can benefit from an ideal BMI achieved over a long-time weight loss process at the cost of aging? We aimed to assess the association between body mass index (BMI) and clinical or neonatal outcomes in patients undergoing in vitro fertilization (IVF) treatment, for answering whether it is necessary to lose weight first for obese patients, particularly those at advanced age.
METHODS: A retrospective cohort study was performed using multicentered data from China. The women were stratified into 5 groups in terms of pre-gravid BMI (kg/m2) with the WHO obesity standard (group 1: BMI < 18.5; group 2: 18.5 ≤ BMI < 23.0; group 3: 23.0 ≤ BMI < 25.0; group 4: 25.0 ≤ BMI < 30.0; group 5: BMI ≥ 30.0). The primary outcome was cumulative live birth rate (CLBR), and other clinical and neonatal outcomes were weighed as secondary outcomes. Multivariate logistic regression analyses were carried to evaluate the association between BMI and the CLBR, or between BMI and some neonatal outcomes. Furthermore, we implemented a machine-learning algorithm to predict the CLBR based on age and BMI.
RESULTS: A total of 115,287 women who underwent first IVF cycles with autologous oocytes from January 2013 to December 2017 were included in our study. The difference in the CLBR among the five groups was statistically significant (P < 0.001). The multivariate logistic regression analysis showed that BMI had no significant impact on the CLBR, while women's age associated with the CLBR negatively. Further, the calculation of the CLBR in different age stratifications among the five groups revealed that the CLBR lowered with age increasing, quantitatively, it decreased by approximately 2% for each one-year increment after 35 years old, while little difference observed in the CLBR corresponding to the five groups at the same age stratification. The machine-learning algorithm derived model showed that BMI's effect on the CLBR in each age stratification was negligible, but age's impact on the CLBR was overwhelming. The multivariate logistic regression analysis showed that BMI did not affect preterm birth, low birth weight infant, small for gestational age (SGA) and large for gestational age (LGA), while BMI was an independent risk factor for fetal macrosomia, which was positively associated with BMI.
CONCLUSIONS: Maternal pre-gravid BMI had no association with the CLBR and neonatal outcomes, except for fetal macrosomia. While the CLBR was lowered with age increasing. For the IVF-pursuing women with obesity plus advanced age, rather than losing weight first, the sooner the treatment starts, the better. A multicentered prospective study with a large size of samples is needed to confirm this conclusion in the future.
A mutated Csf1r gene is disclosed. The mutated Csf1r gene is obtained by changing the 2557th nucleotide of a Csf1r gene from C to A, leading to obtain a mutated protein encoded by the mutated Csf1r gene substitute the 853rd amino acid from proline to threonine. The mutated protein, expression vectors, recombinant viruses, recombinant cells, recombinant bacteria, or recombinant vectors are also disclosed. A method for constructing a murine model with mutations in Csf1r gene. This method includes introducing the targeted vector containing the mutated Csf1r gene into mouse embryonic stem cells, followed by injection into blastocysts to generate F0 generation mice. The F0 generation mice are then bred with mice that specifically express Cre enzyme in tissues, followed by screening. The constructed murine model has significant applications in studying the pathogenic mechanisms of brain diseases caused by microglial cell dysfunction and screening valuable medicine for treating brain diseases.
PURPOSE:To reduce the quantity of information to be recorded while maintaining the picture quality of an original picture as high as possible, by enlarging and interpolating the compressed picture having picture elements forming the original picture sampled at the proper intervals up to the size of the original picture to obtain the deviation between the picture elements of both pictures and recording the deviation picture after reversible compression. CONSTITUTION:An original picture is read out of a magnetic disk by a CPU 14 and a compressed picture for storage is obtained in accordance with a program. This compressed picture includes a basic compressed picture obtained through 1/4 compression, etc. and a deviation compressed picture. In addition, a part of a memory 16 and a memory 17 store the various types of information which are under processing. The CPU 14 records for storage the compressed picture for storage consisting of said two types of compressed pictures into an optical disk 18 according to another program. Then the CPU 14 reads the compressed pictures out of the disk and restores them by the programs.
The Aphasia Rapid Test (ART) was developed and validated originally in French to evaluate language skills in post-stroke patients (Azuar et al., 2013). It is a 26-point scale that takes less than 3 minutes to administer. The simplicity of the ART allows it be used bedside in acute post-stroke patients with little to no training needed. The items needed to administer the ART are also easy to access in healthcare settings (e.g., watch, pen, doctor's coat). Although the ART is not a diagnostic test, it is beneficial for tracking progress and determining prognosis in stroke patients.

The original ART was designed similar to the NIH Stroke Scale (NIHSS), a widely-used test in stroke patients. The NIHSS which assesses many areas of functioning (level of consciousness, gaze, visual ability, facial palsy, motor and sensory ability, limb ataxia, language, dysarthria, and extinction and inattention) was chosen because of its sensitivity to early changes in neurological status and high prognostic accuracy (http://www.nihstrokescale.org). The ART is an expanded version of the language section of the NIHSS. The total possible points on the ART is 26, which indicates the highest level of impairment. The test begins with the patient being asked to follow two one-step commands (up to two points each), a complex command (up to 3 points), repeat three nouns (up to 6 points), repeat a simple sentence (up to 2 points), and name three simple objects (up to 6 points). The next item requires a rating of dysarthria by the examiner (up to 3 points). On the final item, the patient is asked to name as many animals as they can think of in one minute (up to 4 points). With the exception of items 1a, 1b, and 6, there are no time restrictions on the test.

The purpose of the present study is to translate the original ART into Turkish to provide an efficient method for the evaluation of language skills in post-stroke Turkish-speaking patients and to assess its inter-rater reliability.
This invention reports a drug for hyperphospheremia and its preparative method. The preparation includes active constituents, lanthanum polystyrene sulfonate, and excipients. The preparative method in the invention can be summarized as follows: Polystyrene sulfonic acid is obtained by treating polystyrene sulfosalt with hydrochloric acid, soaked or eluted with water soluble lanthanum-contained solution, and washed with water till its PH is neutral. Then, the lanthanum polystyrene sulfonate solution is washed till the superfluous La −  unexchanged is washed out. Lanthanum polystyrene sulfonate is taken out and crushed to powder after being dried. The lanthanum polystyrene sulfonate, whose weight percentage of lanthanum is 14-22%, is used as active constituents to prepare gastrointestinal tract preparations together with general amount of excipients with routine preparative method. In the invention, lanthanum polystyrene sulfonate is adopted as active constituents, mixed with excipients, and the preparation is obtained. It makes phosphate in alimentary tract become insoluble conjugates after gastrointestinal tract administration. The insoluble conjugates would be discharged. Thus, the drug can achieve the purpose of treating hyperphospheremia.
This is a prospective, randomized controlled, superiority trial. The study population consists of patients after ESD for mucosal lesions at Xijing Hospital. In the control arm, patients after ESD are informed on follow-up instructions by doctors about the follow-up requirements before discharge, and complete a questionnaire without compliance-related education. In the questionnaire arm, in addition to receiving the same follow-up instructions as the control arm, patients need to complete a questionnaire on compliance-related education before discharge. Based on the responses, nurses provide feedback and guidance. Patients and doctors will be blind to the group of patients during the trial process. Our objective is to evaluate whether completing a questionnaire and receiving feedback on compliance-related education can improve patient compliance with post-ESD endoscopic surveillance, in comparison to those who did not complete the compliance-related education questionnaire. Additionally, the investigators intend to investigate the factors that influence patient compliance.

Part 1 will assess whether the completion of questionnaire and feedback on compliance-related education can improve short-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing short-term patient compliance. Part 1 will be expected to include 220 post-ESD patients randomized 1:1 into the questionnaire arm and control arm. Sample size calculation is based on short-term compliance data from a pilot trial, with a 20% difference between the two groups. Under the conditions of an α error of 5% (in a one-sided test) and power of 80%, assuming a superiority margin of 5%, a sample size of 220 cases is required.

Part 2 will assess whether the completion of questionnaire and feedback on compliance-related education can improve long-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing patient compliance. Part 2 will be expected to include 500 post-ESD patients randomized 1:1 into the questionnaire arm and control arm. Under the conditions of an α error of 5% (in a one-sided test) and power of 80%, assuming a 20% difference between the two groups in long-term compliance outcome, a superiority margin of 10%, and rounding up, a sample size of 500 cases is required.
OPSYNVI is taken orally once daily with or without food. Swallow the tablets whole, with water. Do not cut, crush, or chew tablets. If the patient misses a dose of OPSYNVI, tell the patient to take it as soon as possible and then take the next dose at the regularly scheduled time. Tell the patient not to take two doses at the same time if a dose has been missed.

For patients who are treatment-naïve to any PAH specific therapy or transitioning from ERA monotherapy

The recommended starting dose of OPSYNVI is one 10 mg/20 mg tablet taken orally once daily with or without food for one week. If tolerated, up titrate OPSYNVI to one 10 mg/40 mg tablet taken orally once daily with or without food as the maintenance dose.

For patients transitioning from PDE5 inhibitor monotherapy or PDE5 inhibitor and ERA therapy in combination

The recommended dose of OPSYNVI is one 10 mg/40 mg tablet taken orally once daily.
Participants aged 40-65 years will receive the self-administered FIT test by mail including instructions for obtaining and returning their stool specimens. Participants will be in this group for up to 6 months.
The coronavirus disease 2019 (COVID-19) pandemic has affected multiple aspects of everyday life worldwide. Pandemics unleash a societal sense of fear and anxiety. Hence, the COVID-19 pandemic have had a profound impact on mental health. This has led to substantial research on this topic; however, literature evaluating the mental health effects of the pandemic on small groups of people is scarce. Healthcare workers have undergone significant psychological pressure and stress during viral surges of this pandemic. Furthermore, the levels of anxiety vary as the number of cases varies between regions and across time.

After approval by the Institutional Review Board (Protocol # 160167), a cross-sectional study was conducted to identify anxiety levels during the COVID-19 pandemic among anesthesia providers at our institution. The participants included Faculty anesthesiologists, anesthesiology residents, Certified Registered Nurse Anesthetists, and Nurse Anesthetists students. Data were collected from August 26 to September 15, 2020. A questionnaire containing the General Anxiety Disorder-7 (GAD-7) scale, followed by a set of questions with binary answers to evaluate the presence or absence of anxiety-related factors during the COVID-19 pandemic, was administered through direct approach and voluntary participation of the subjects.
Sensory motor rhythm neurofeedback: The subjects will perform 60 minutes per week for 10 weeks, with a total training time of 600 minutes. The intervention in this trial lasts for 10 weeks (1 time/week), with the goal of improving sensory motor rhythm. Since this training uses visual and auditory feedback, if patients are assigned to this group, they will be ask to wear an EEG cap with 19 electrodes. They can take a relaxed sitting posture and choose animations (e.g., puzzles, mazes, and other feedback content), and then focus on computer screen animation for training, each training time is approximately 60 minutes.
The present invention provides a transfusion monitoring method. A gravity sensor is adopted for collecting a gross weight signal which comprises the weight of liquid medicine and weight of accessory. A microprocessor analyzes the gross weight signal for obtaining the gross weight. The microprocessor is adopted for calculating the reduction amount of the gross weight in a preset time period, calculates the current weight of liquid medicine in a transfusion container in real time, namely a difference between an initial weight Wo of the liquid medicine and the reduction amount deltaW. Then the following transfusion parameters are calculated: a transfusion speed, the time required for finishing transfusion, and a residual liquid medicine ratio. An alarm signal is generated when the weight of the current liquid medicine is equal with or less than a critical alarm point. The transfusion monitoring method has the following advantages: accurate and timely sampling and accurate calculation as the high-sensitivity gravity sensor and the microprocessor which comprises analysis software are used, convenient operation and use of the nurse, high stability, high reliability, low cost, and capacity for network accessing. The dynamic change process of the transfusion process can be monitored in real time. A problem that various conveniences exist in liquid dropping of transfusion is settled for the nurse and the patient.
Isolates of HIV-1 with reduced susceptibility to the drug have been recovered from some patients treated with indinavir. Viral resistance was correlated with the accumulation of mutations that resulted in the expression of amino acid substitutions in the viral protease. Eleven amino acid residue positions, (L10l/V/R, K20l/M/R, L24l, M46l/L, l54A/V, L63P, l64V, A71T/V, V82A/F/T, l84V, and L90M), at which substitutions are associated with resistance, have been identified. Resistance was mediated by the co-expression of multiple and variable substitutions at these positions. No single substitution was either necessary or sufficient for measurable resistance (≥4-fold increase in IC95). In general, higher levels of resistance were associated with the co-expression of greater numbers of substitutions, although their individual effects varied and were not additive. At least 3 amino acid substitutions must be present for phenotypic resistance to indinavir to reach measurable levels. In addition, mutations in the p7/ p1 and p1/ p6 gag cleavage sites were observed in some indinavir resistant HIV-1 isolates.

In vitro phenotypic susceptibilities to indinavir were determined for 38 viral isolates from 13 patients who experienced virologic rebounds during indinavir monotherapy. Pre-treatment isolates from five patients exhibited indinavir IC95 values of 50-100 nM. At or following viral RNA rebound (after 12-76 weeks of therapy), IC95 values ranged from 25 to >3000 nM, and the viruses carried 2 to 10 mutations in the protease gene relative to baseline.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical antiestrogenic and antiandrogenic preparation has an effective amount of raloxyphene hydrochloride, polyvinylpyrrolidone, a surface-active substance and water-soluble diluting agent. Fatty acid sorbitane ester is used as a surface-active substance and polyol or sugar is used as a water-soluble diluting agent. EFFECT: new preparation shows increased solubility in an aqueous medium and enhanced biological availability. enhanced effectiveness of preparation. 9 cl, 3 dwg, 18 ex
Achieving WHO cervical cancer elimination goals will necessitate efforts to increase HPV vaccine access and coverage in low-and-middle-income countries (LMICs). Although LMICs account for the majority of cervical cancer cases globally, scale-up of HPV vaccine programs and progress toward coverage targets in LMICs has been largely insufficient. Understanding the barriers and facilitators that stakeholders face in the introduction and scale-up of HPV vaccination programs will be pivotal in ensuring that LMICs are equipped to optimize the implementation of HPV vaccination programs. This qualitative study interviewed 13 global stakeholders categorized as either academic partners or global immunization partners to ascertain perspectives regarding factors affecting the introduction and scale-up of HPV vaccination programs in LMICs. Global stakeholders were selected as their perspectives have not been as readily highlighted within the literature despite their key role in HPV vaccination programming. The results of this investigation identified upstream (e.g., financial considerations, vaccine prioritization, global supply, capacity and delivery, and vaccine accessibility, equity, and ethics) and downstream (e.g., vaccine acceptability and hesitancy, communications, advocacy, and social mobilization) determinants that impact program introduction and scale-up and confirmed that strong political commitment and governance are significant in garnering support for HPV vaccines. As LMICs introduce HPV vaccines into their national immunization programs and develop plans for scaling up vaccination efforts, strategic approaches to communications and advocacy will also be needed to successfully meet coverage targets.